Cargando…

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT

Background: 68Ga-PSMA-11 PET/CT is a promising method for the assessment of local recurrence (LR) in prostate cancer (PCa) patients. The aim of this study was to evaluate the diagnostic performance of early 68Ga-PSMA-11 PET imaging in comparison to 68Ga-PSMA-11 PET imaging 60 min post-injection (p.i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayerschmidt, Steffen, Uprimny, Christian, Kroiss, Alexander Stephan, Fritz, Josef, Nilica, Bernhard, Svirydenka, Hanna, Decristoforo, Clemens, von Guggenberg, Elisabeth, Horninger, Wolfgang, Virgolini, Irene Johanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304119/ https://www.ncbi.nlm.nih.gov/pubmed/34208989 http://dx.doi.org/10.3390/diagnostics11071191

Ejemplares similares

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
por: Virgolini, Irene, et al.
Publicado: (2016)

Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction
por: Lawhn-Heath, Courtney, et al.
Publicado: (2018)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of (68)Ga-FAPI PET/CT
por: Sviridenko, Anna, et al.
Publicado: (2022)

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
por: von Eyben, Rie, et al.
Publicado: (2022)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study
por: Bauckneht, Matteo, et al.
Publicado: (2023)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles
por: Rangger, Christine, et al.
Publicado: (2013)

Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survival
por: Lindner, Andrea Katharina, et al.
Publicado: (2019)

Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
por: Gruber, Leonhard, et al.
Publicado: (2022)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
por: Nilica, Bernhard, et al.
Publicado: (2016)

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461
por: von Eyben, Rie, et al.
Publicado: (2023)

Mesorectal Lymph Node Metastases as Index Lesion in (68)Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
por: Leitsmann, Conrad, et al.
Publicado: (2021)

Furosemide and albumin for diuresis of edema (FADE): a study protocol for a randomized controlled trial
por: Oczkowski, Simon JW, et al.
Publicado: (2014)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Comparison between [(68)Ga]Ga-PSMA-617 and [(18)F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma
por: Brighi, Caterina, et al.
Publicado: (2023)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
por: Adin, Darcy, et al.
Publicado: (2021)

Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
por: Margail, Charles, et al.
Publicado: (2023)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Goal-directed diuresis: A case — control study of continuous furosemide infusion in critically ill trauma patients
por: Yeh, Daniel Dante, et al.
Publicado: (2015)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
por: Kulkarni, Meghana, et al.
Publicado: (2019)

A novel read methodology to evaluate the optimal dose of (68)Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
por: Miller, Colin G., et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
por: Grubmüller, B., et al.
Publicado: (2017)

Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent—Impact of Delayed Imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT
por: Christensen, Mads T., et al.
Publicado: (2022)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rgl1m889c3fhqggvhva0lho2co